[시장보고서]세계의 타미플루(인산오셀타미비르) 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2034년)

세계의 타미플루(인산오셀타미비르) 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2034년)

Tamiflu (Oseltamivir Phosphate) Market (Drug Type: Branded, and Generic; Dosage: Capsule, and Suspension; and Indication: Influenza A, Influenza B, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

상품코드 : 1531001

리서치사 : Transparency Market Research

발행일 : 2024년 06월

페이지 정보 : 영문 187 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,366,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 12,698,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,029,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

타미플루(인산오셀타미비르) 시장 - 조사 범위

TMR의 조사 보고서 '타미플루(인산오셀타미비르) 세계 시장'은 2024년부터 2034년까지의 예측 기간에 시장 지표에 대한 귀중한 통찰력을 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회에 대해서 또한 조사했습니다. 본 보고서는 2024년을 기준년, 2034년을 예측년으로 하여 2018년부터 2034년까지 세계의 타미플루(인산오셀타미비르) 시장의 수익과 예측을 제공합니다. 또한 2024년부터 2034년까지 세계의 타미플루(인산오셀타미비르) 시장의 복합 연간 성장률(CAGR%)도 제공합니다.

이 보고서는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서 분석가는 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체와의 인터뷰를 실시했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참조하여 타미플루(인산 오셀타미비르) 시장을 추찰했습니다.

시장 현황
2023년 시장 규모	19억 달러
2034년 시장 규모	27억 달러
CAGR	3.3%

본 보고서에서는 세계의 타미플루(인산오셀타미비르) 시장 경쟁 구도를 조사했습니다. 세계의 타미플루(인산오셀타미비르) 시장에서 사업을 전개하는 주요 기업이 확인되어 각 기업이 다양한 속성으로 프로파일 되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT 등이 본 보고서에서 소개되고 있는 세계의 타미플루(인산 오셀타미비르) 시장에서의 기업의 속성입니다.

시장 기업-경쟁 매트릭스(기업 Tier과 규모별)
시장 점유율 분석기업별(2022년)
기업 프로파일
- F. Hoffmann-La Roche Ltd.
- NATCO Pharma Limited
- Teva Pharmaceutical Industries Ltd
- LUPIN Limited
- Amneal pharmaceuticals LLC
- Zydus Cadila
- Sun Pharmaceutical Industries Ltd.
- Alembic Pharmaceuticals Limited
- Mylan NV
- Hetero Group

JHS

영문 목차

영문목차

Tamiflu (Oseltamivir Phosphate) Market - Scope of Report

TMR's report on the global tamiflu (oseltamivir phosphate) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global tamiflu (oseltamivir phosphate) market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global tamiflu (oseltamivir phosphate) market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the tamiflu (oseltamivir phosphate) market.

Market Snapshot
Market Value in 2023	US$ 1.9 Bn
Market Value in 2034	US$ 2.7 Bn
CAGR	3.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global tamiflu (oseltamivir phosphate) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global tamiflu (oseltamivir phosphate) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global tamiflu (oseltamivir phosphate) market.

The report delves into the competitive landscape of the global tamiflu (oseltamivir phosphate) market. Key players operating in the global tamiflu (oseltamivir phosphate) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global tamiflu (oseltamivir phosphate) market profiled in this report.

Key Questions Answered in Global tamiflu (oseltamivir phosphate) Market Report:

What is the sales/revenue generated by tamiflu (oseltamivir phosphate) across all regions during the forecast period?
What are the opportunities in the global tamiflu (oseltamivir phosphate) market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Tamiflu (Oseltamivir Phosphate) Market - Research Objectives and Research Approach

The comprehensive report on the global tamiflu (oseltamivir phosphate) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global tamiflu (oseltamivir phosphate) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global tamiflu (oseltamivir phosphate) market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Tamiflu (Oseltamivir Phosphate) Market

4. Market Overview

4.1. Introduction
- 4.1.1. Drug Type Definition
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, 2020-2034
- 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Influenza Flu Prevalence Globally
5.2. Porter's Five Forces Analysis
5.3. Key Industry Events
5.4. Regulatory Scenario

6. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Drug Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020-2034
- 6.3.1. Branded
- 6.3.2. Generic
6.4. Market Attractiveness By Drug Type

7. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Dosage

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Dosage, 2020-2034
- 7.3.1. Capsule
- 7.3.2. Suspension
7.4. Market Attractiveness By Dosage

8. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Indication

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Indication, 2020-2034
- 8.3.1. Influenza A
- 8.3.2. Influenza B
- 8.3.3. Others
8.4. Market Attractiveness By Indication

9. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Distribution Channel

9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Distribution Channel, 2020-2034
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
- 9.3.4. Others
9.4. Market Attractiveness By Distribution Channel

10. Global Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecasts, By Region

10.1. Key Findings
10.2. Market Value Forecast By Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region

11. North America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2020-2034
- 11.2.1. Branded
- 11.2.2. Generic
11.3. Market Value Forecast By Dosage, 2020-2034
- 11.3.1. Capsule
- 11.3.2. Suspension
11.4. Market Value Forecast By Indication, 2020-2034
- 11.4.1. Influenza A
- 11.4.2. Influenza B
- 11.4.3. Others
11.5. Market Value Forecast By Distribution Channel, 2020-2034
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
- 11.5.4. Others
11.6. Market Value Forecast By Country, 2020-2034
- 11.6.1. U.S.
- 11.6.2. Canada
11.7. Market Attractiveness Analysis
- 11.7.1. By Drug Type
- 11.7.2. By Dosage
- 11.7.3. By Indication
- 11.7.4. By Distribution Channel
- 11.7.5. By Country

12. Europe Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020-2034
- 12.2.1. Branded
- 12.2.2. Generic
12.3. Market Value Forecast By Dosage, 2020-2034
- 12.3.1. Capsule
- 12.3.2. Suspension
12.4. Market Value Forecast By Indication, 2020-2034
- 12.4.1. Influenza A
- 12.4.2. Influenza B
- 12.4.3. Others
12.5. Market Value Forecast By Distribution Channel, 2020-2034
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
- 12.5.4. Others
12.6. Market Value Forecast By Country, 2020-2034
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Italy
- 12.6.5. Spain
- 12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
- 12.7.1. By Drug Type
- 12.7.2. By Dosage
- 12.7.3. By Indication
- 12.7.4. By Distribution Channel
- 12.7.5. By Country

13. Asia Pacific Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020-2034
- 13.2.1. Branded
- 13.2.2. Generic
13.3. Market Value Forecast By Dosage, 2020-2034
- 13.3.1. Capsule
- 13.3.2. Suspension
13.4. Market Value Forecast By Indication, 2020-2034
- 13.4.1. Influenza A
- 13.4.2. Influenza B
- 13.4.3. Others
13.5. Market Value Forecast By Distribution Channel, 2020-2034
- 13.5.1. Hospital Pharmacies
- 13.5.2. Retail Pharmacies
- 13.5.3. Online Pharmacies
- 13.5.4. Others
13.6. Market Value Forecast By Country, 2020-2034
- 13.6.1. China
- 13.6.2. India
- 13.6.3. Japan
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
- 13.7.1. By Drug Type
- 13.7.2. By Dosage
- 13.7.3. By Indication
- 13.7.4. By Distribution Channel
- 13.7.5. By Country

14. Latin America Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020-2034
- 14.2.1. Branded
- 14.2.2. Generic
14.3. Market Value Forecast By Dosage, 2020-2034
- 14.3.1. Capsule
- 14.3.2. Suspension
14.4. Market Value Forecast By Indication, 2020-2034
- 14.4.1. Influenza A
- 14.4.2. Influenza B
- 14.4.3. Others
14.5. Market Value Forecast By Distribution Channel, 2020-2034
- 14.5.1. Hospital Pharmacies
- 14.5.2. Retail Pharmacies
- 14.5.3. Online Pharmacies
- 14.5.4. Others
14.6. Market Value Forecast By Country, 2020-2034
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
- 14.7.1. By Drug Type
- 14.7.2. By Dosage
- 14.7.3. By Indication
- 14.7.4. By Distribution Channel
- 14.7.5. By Country

15. Middle East & Africa Tamiflu (Oseltamivir Phosphate) Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast By Drug Type, 2020-2034
- 15.2.1. Branded
- 15.2.2. Generic
15.3. Market Value Forecast By Dosage, 2020-2034
- 15.3.1. Capsule
- 15.3.2. Suspension
15.4. Market Value Forecast By Indication, 2020-2034
- 15.4.1. Influenza A
- 15.4.2. Influenza B
- 15.4.3. Others
15.5. Market Value Forecast By Distribution Channel, 2020-2034
- 15.5.1. Hospital Pharmacies
- 15.5.2. Retail Pharmacies
- 15.5.3. Online Pharmacies
- 15.5.4. Others
15.6. Market Value Forecast By Country, 2020-2034
- 15.6.1. GCC
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
- 15.7.1. By Drug Type
- 15.7.2. By Dosage
- 15.7.3. By Indication
- 15.7.4. By Distribution Channel
- 15.7.5. By Country

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2022)
16.3. Company Profiles
- 16.3.1. F. Hoffmann-La Roche Ltd.
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. NATCO Pharma Limited
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Teva Pharmaceutical Industries Ltd
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. LUPIN Limited
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. Amneal pharmaceuticals LLC
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Zydus Cadila
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Sun Pharmaceutical Industries Ltd.
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Alembic Pharmaceuticals Limited
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Mylan N.V.
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. Hetero Group
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Product Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview

한글목차

타미플루(인산오셀타미비르) 시장 - 조사 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약: 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장 분석과 예측 : 약제 유형별

제7장 세계 시장 분석과 예측 : 용량별

제8장 세계 시장 분석과 예측 : 적응증별

제9장 세계 시장 분석과 예측 : 유통 채널별

제10장 세계 시장 분석과 예측 : 지역별

제11장 북미 시장 분석과 예측

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측

제16장 경쟁 구도